Education
About Us
Working with TipRanks
Follow Us
MaxCyte Inc (MXCT)
NASDAQ:MXCT
MXCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.00 - $5.20
Previous CloseN/A
Volume471.30K
Average Volume (3M)1.04M
Market Cap
£233.90M
Enterprise Value$169.80M
Total Cash (Recent Filing)£23.39M
Total Debt (Recent Filing)£18.82M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 06, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding106,318,535
10 Day Avg. Volume949,223
30 Day Avg. Volume1,040,674
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£6.78Price Target Upside232.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Industry GrowthMXCT is tied to the rapidly growing CGT industry, which is expected to continue to grow at a 30%+ CAGR through the end of the decade.
Partnerships And AgreementsMXCT delivered a record 6 SPL agreements in 2024, and ended 2024 with 28 active SPL agreements, including 18 that are active in the clinic and one that is commercial.
Strong Balance SheetMXCT held $190M of cash at Q4'24 and holds no debt.
Bears Say
Capital Purchases HesitancyBiopharma customers have become more hesitant to make capital purchases of its systems, and this trend intensified.
Market PressureShares are down 34% year-to-date reflecting broader market pressure on longer-duration assets, macro uncertainty, and its possible impact on MaxCyte’s customers.
Revenue GuidanceThe 2025 revenue guide was lower than expected, particularly for core organic growth.
MaxCyte News
MXCT FAQ
What was MaxCyte Inc’s price range in the past 12 months?
MaxCyte Inc lowest stock price was $2.00 and its highest was $5.20 in the past 12 months.
What is MaxCyte Inc’s market cap?
MaxCyte Inc’s market cap is £233.90M.
When is MaxCyte Inc’s upcoming earnings report date?
MaxCyte Inc’s upcoming earnings report date is Aug 06, 2025 which is tomorrow.
How were MaxCyte Inc’s earnings last quarter?
Currently, no data Available
Is MaxCyte Inc overvalued?
According to Wall Street analysts MaxCyte Inc’s price is currently Undervalued.
Does MaxCyte Inc pay dividends?
MaxCyte Inc does not currently pay dividends.
What is MaxCyte Inc’s EPS estimate?
MaxCyte Inc’s EPS estimate is -0.1.
How many shares outstanding does MaxCyte Inc have?
MaxCyte Inc has 106,318,535 shares outstanding.
What happened to MaxCyte Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MaxCyte Inc?
Currently, no hedge funds are holding shares in MXCT
Company Description
MaxCyte Inc
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
MaxCyte (MXCT) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
MXCT Stock 12 Month Forecast
Average Price Target
$6.78
▲(232.15%Upside)
Technical Analysis
Ownership Overview
0.68% Insiders
14.30% Mutual Funds
30.94% Other Institutional Investors
75.37% Public Companies and
Individual Investors